Merck (MRK) announced the opening of a new, $1B, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site. This expansion of our Durham plant is a crucial component of the more than $12B Merck has invested toward U.S. capital investment since 2018 focused on expanding domestic manufacturing and research and development capabilities and creating new jobs in the U.S., with another $8B of U.S. capital investment expected by 2028.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- CDC plans study into potential vaccines, autism connections, Reuters reports
- Dow Jones Dips Ahead of Jerome Powell Comments
- Hold Rating for Merck & Company Amid Keytruda Patent Infringement Concerns
- Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
- Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Questions or Comments about the article? Write to editor@tipranks.com